Almirall to Begin Phase 3 Study of Lebrikizumab in Nummular Eczema

Almirall is starting a Phase 3 study assessing the efficacy and safety of lebrikizumab (Ebglyss), currently approved for the treatment of moderate-to-severe atopic dermatitis, in patients with nummular eczema.

This study will be initiated in the first half of 2026.

LumiNE is a Phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter clinical trial with a double-blind extension evaluating efficacy, safety, and tolerability of lebrikizumab for up to 48 weeks of treatment in adult participants with nummular eczema who are not adequately controlled with topical corticosteroids or when this treatment is not medically advisable.

The study will initially randomize approximately 270 participants at around 60 centers across Europe, with a potential extension to additional patients. The primary endpoint is the improvement of IGA-NE (Investigator’s Global Assessment of nummular eczema), and the key secondary endpoints are pruritus NRS (Numerical Rating Scale) improvement from baseline and absolute change in DLQI (Dermatology Life Quality Index).

“We are excited to start this Phase 3 study with lebrikizumab in patients suffering from nummular eczema as it has the potential to make a meaningful difference in the treatment of this debilitating disease. The proven efficacy of lebrikizumab in atopic dermatitis, its high affinity to the cytokine interleukin (IL)-13, and the scientific evidence pointing to a central role of IL-13 also in nummular eczema could enable us to expand the benefits of lebrikizumab to these patients, in line with Almirall’s purpose to transform people’s lives,” says Karl Ziegelbauer, Chief Scientific Officer at Almirall, in a news release.

“This is an important clinical study as it is aimed at addressing the unmet needs of patients living with nummular eczema, and the latest scientific insights that show a potential role of IL-13 in the development of this debilitating chronic skin disease. We are looking forward to initiating this Phase 3 study as soon as possible and to assessing the potential for lebrikizumab to extend its benefits to addressing nummular eczema,” adds LumiNE coordinating investigator Kilian Eyerich, MD, PhD, Medical Director of the Department of Dermatology and Venereology at the Medical Center University of Freiburg in Freiburg, Germany.

Lebrikizumab was approved in Europe in October 2023 and in the US in August 2024. Almirall has exclusive rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe. Almirall’s partner Lilly has exclusive rights for development and commercialization of Lebrikizumab in the US and the rest of the world outside Europe.